In that regard, targeting MET may prove beneficial for GBM therapy, where strategies to regulate the MET/HGF pathway have led to the development of several types of inhibitors: small-molecule tyrosine kinase inhibitors, monoclonal antibodies to the MET receptor and antagonists or monoclonal antibodies to HGF (Figure 2) [18]. The gene discussed is HGF; the disease is glioblastoma.